Physician profile
Donetta L Sinard
NPI 1073175311
$6,745.75
in general payments reported to CMS, 2019-2025
59 companies · $1,997 in 2025
The $1,997 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $911 · 2022: $1,021 · 2023: $1,372 · 2024: $1,445 · 2025: $1,997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,444 · Education: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,443.96 |
| Education | $369.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $503.91 | 2021-2025 | Tagrisso, Calquence, Enhertu |
| Novartis Pharmaceuticals Corporation | $424.29 | 2022-2025 | |
| Incyte Corporation | $408.77 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Janssen Biotech, INC. | $360.78 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Seagen INC. | $339.50 | 2021-2025 | Adcetris, Tukysa, Padcev |
| Merck Sharp & Dohme LLC | $318.08 | 2021-2025 | Keytruda, Lynparza, Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $309.95 | 2021-2025 | Ninlaro, Alunbrig |
| Genzyme Corporation | $293.73 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $249.43 | 2021-2025 | Opdivo, Opdualag, Augtyro |
| Pfizer INC. | $235.33 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $200.67 | 2021-2025 | Libtayo |
| Daiichi Sankyo INC. | $192.65 | 2022-2025 | Enhertu, Datroway |
| Celgene Corporation | $180.82 | 2021-2025 | Reblozyl |
| Alexion Pharmaceuticals, INC. | $163.46 | 2021-2025 | Ultomiris |
| Astellas Pharma US INC | $147.77 | 2022-2025 | Padcev, Xospata, Vyloy |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donetta Sinard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.